[#item_full_content] The program will cover the latest clinical insights on medical cannabis, examine cannabinoid science and therapeutics, and present evidence-based strategies. Public policy is a major focus, including legislative updates on Pennsylvania’s opioid crisis and urgent issues like xylazine. 
Read More
